Literature DB >> 23551022

How should we define and classify exacerbations in chronic obstructive pulmonary disease?

Juan Antonio Trigueros Carrero1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic disorder whose clinical course may be punctuated by exacerbations characterized by a sudden symptom worsening beyond the expected daily variations. Exacerbations bear clinical and prognostic relevance, and may result in marked functional and clinical deterioration. The varying presentations of COPD mean that exacerbations, although more frequent in patients with severe or very severe disease, may occur regardless of the degree of functional impairment. The new Spanish COPD Guideline (GesEPOC) has provided new insights into the management of the disease. The GesEPOC defines various disease phenotypes with different clinical, prognostic and therapeutic implications. One of these phenotypes is the so-called 'exacerbator', characterized by the incidence of an increased number of exacerbations (two or more moderate-severe exacerbations in the last year). An exacerbation must be defined by: an increase in symptom intensity occurring after a certain period of time since the last exacerbation (so that treatment failure can be excluded as the cause of the event); and the contribution of social criteria or reasons concerning the choice of therapy. The availability of certain tools to detect exacerbations would enable establishment of a homogeneous definition of exacerbation, and improved diagnosis, a suitable treatment choice and a more appropriate patient selection for clinical studies. Validated clinical questionnaires and biomarkers are the most helpful instruments to reach the above objectives. Following the clinical diagnosis of a COPD exacerbation, associated comorbidities must be evaluated and an etiologic diagnosis must be made, all of which will partially drive the choice of treatment. Once a diagnosis has been made, the severity of the exacerbation should be established in order to define where and how the patient should be treated. Based on the patient's clinical history, clinical examination and diagnostic tests, the severity will be classified in one of these four degrees: very severe, severe, moderate and mild.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551022     DOI: 10.1586/ers.13.16

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  6 in total

1.  No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease.

Authors:  Josef Yayan
Journal:  Int J Med Sci       Date:  2015-03-02       Impact factor: 3.738

2.  A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation.

Authors:  Soo Han Kim; Hee-Sung Ahn; Jin-Soo Park; Jeonghun Yeom; Jiyoung Yu; Kyunggon Kim; Yeon-Mok Oh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-01

3.  Identifying acute exacerbations of chronic obstructive pulmonary disease using patient-reported symptoms and cough feature analysis.

Authors:  Scott Claxton; Paul Porter; Joanna Brisbane; Natasha Bear; Javan Wood; Vesa Peltonen; Phillip Della; Claire Smith; Udantha Abeyratne
Journal:  NPJ Digit Med       Date:  2021-07-02

4.  Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data.

Authors:  Christine L Baker; Kelly H Zou; Jun Su
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-03

5.  Do symptom-based questions help screen COPD among Chinese populations?

Authors:  Qun Zhang; Min Wang; Xiaona Li; Hong Wang; Jianming Wang
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

6.  Comparison of patient-reported outcomes during acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Koichi Nishimura; Saya Nakamura; Masaaki Kusunose; Kazuhito Nakayasu; Ryo Sanda; Yoshinori Hasegawa; Toru Oga
Journal:  BMJ Open Respir Res       Date:  2018-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.